Promising combo for tough breast cancer hits early roadblock
NCT ID NCT04216472
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This phase 2 trial tested a combination of nab-paclitaxel (a chemotherapy) and alpelisib (a targeted drug) in people with triple-negative breast cancer that has specific genetic changes (PIK3CA or PTEN) and did not respond to standard chemotherapy. The goal was to see if the combo could shrink tumors before surgery. However, the study was terminated early after enrolling only 6 participants, so we have very little data on how well it works or its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nab-paclitaxel (a chemotherapy drug) and alpelisib (a targeted therapy)
What this could lead to
If successful, this combination could shrink tumors before surgery in a hard-to-treat breast cancer type.
What could go wrong
The trial was terminated early with only 6 participants, so results are very limited. It is a small, early-phase study, and the treatment may not work or may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.